Specialised Therapeutics has secured an Australian Pharmaceutical Benefits Scheme listing for Minjuvi, or tafasitamab, in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma grades 1 to 3a. The listing took effect on August 1, 2026, converting the regimen’s April 2026 Therapeutic Goods Administration registration into subsidised access for eligible patients treated through Australian hospitals.
The three-drug regimen targets CD19 and CD20 through complementary immune-mediated mechanisms and does not include conventional cytotoxic chemotherapy. Specialised Therapeutics has described it as Australia’s first and only PBS-funded chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination for this population, as well as the first new therapy reimbursed for relapsed or refractory follicular lymphoma in nine years. Those descriptions originate from the company, but the underlying access milestone is clear: a treatment supported by a large randomised Phase 3 trial is now available through the public reimbursement system rather than relying on unfunded access.
The distinction matters because regulatory registration and reimbursement solve different problems. Therapeutic Goods Administration registration establishes that the medicine can be supplied for the approved indication, while the Pharmaceutical Benefits Scheme listing addresses affordability and practical access. Minjuvi remains an Authority Required medicine, meaning clinicians must confirm that patients satisfy the applicable PBS criteria before subsidised treatment can proceed.
Why does the Minjuvi PBS listing represent more than another regulatory milestone?
The PBS has created separate items covering initial treatment during cycles one to five and continuing treatment during cycles six to 12, with corresponding listings for public and private hospital use. The published items allow a maximum amount of 1,400 mg and show dispensed prices exceeding A$8,300, while the listed general patient charge is capped at A$25. These figures do not represent the full cost of a complete treatment course because tafasitamab is dosed according to body weight and administered repeatedly, but they illustrate why reimbursement is central to meaningful access.
The reimbursement pathway was not automatic. The Pharmaceutical Benefits Advisory Committee deferred the submission in November 2025 because the Therapeutic Goods Administration’s evaluation had not been sufficiently advanced for a recommendation to be finalised. The committee subsequently recommended listing at its March 2026 meeting after the Australian regulator supported tafasitamab’s registration.
That recommendation also exposed the economic and evidentiary negotiation behind the eventual listing. The committee considered the sponsor’s proposed survival assumptions too optimistic, sought a lower price that reflected more conservative estimates of benefit and called for a risk-sharing arrangement to address uncertainty around eligible patient numbers. The PBS decision therefore represents a negotiated balance between clinical value, budget impact and unresolved long-term evidence rather than an unrestricted endorsement of every commercial claim made for the regimen.
This is an important nuance for industry observers. A reimbursement decision can validate a product’s health-system relevance while still attaching conditions designed to contain financial risk. For Specialised Therapeutics, securing both registration and reimbursement within several months reduces the delay between formal approval and real-world availability. For Australian haematology services, however, uptake will still depend on authority processing, patient selection, infusion capacity and management of the regimen’s safety profile.
What did the Phase 3 inMIND trial establish about progression-free survival?
The Australian registration and PBS submission were supported principally by the inMIND study, a global Phase 3, double-blind, randomised and placebo-controlled trial conducted at 210 centres. The follicular lymphoma analysis included 548 adults whose disease had relapsed or become refractory after at least one previous systemic therapy. Participants were assigned to receive tafasitamab or placebo, with both groups also receiving lenalidomide and rituximab.
The study was designed to test the incremental contribution of tafasitamab rather than compare the complete combination directly against chemotherapy. Patients in the experimental group received tafasitamab at 12 mg per kilogram by intravenous infusion, initially every week and later twice per 28-day cycle. Lenalidomide was administered orally on days one to 21 for up to 12 cycles, while rituximab was delivered during the first five cycles.
Investigator-assessed median progression-free survival was 22.4 months in the tafasitamab group, compared with 13.9 months in the placebo group. The hazard ratio was 0.43, corresponding to a 57 percent relative reduction in the risk of progression, relapse or death during the analysed period. The result was statistically significant, and an independent review committee produced findings consistent with the investigator assessment.
The 57 percent figure should not be interpreted as showing that 57 percent of patients were cured, nor does it mean that survival was extended by 57 percent. It describes the relative difference in the rate at which progression, relapse or death occurred between the randomised groups over the trial’s follow-up. Progression-free survival is clinically relevant in a disease characterised by repeated relapses, but it is not interchangeable with longer overall survival or a definitive improvement in every patient’s quality of life.
The Pharmaceutical Benefits Advisory Committee specifically noted that the available evidence did not clearly demonstrate an overall survival improvement. This does not invalidate the progression-free survival result, but it limits how broadly the findings can be translated into claims about longevity. Longer follow-up will be needed to determine whether delaying progression leads to a durable survival advantage, a longer interval before subsequent therapy or other benefits that remain meaningful across successive treatment lines.
Why does chemotherapy-free treatment not necessarily mean treatment with minimal toxicity?
The chemotherapy-free label is likely to attract attention because many patients with follicular lymphoma receive repeated therapies across the course of their disease. Avoiding conventional chemotherapy may reduce exposure to certain cumulative toxicities, but it does not make the Minjuvi regimen free from substantial adverse effects, monitoring requirements or treatment burden.
Tafasitamab is an Fc-modified monoclonal antibody directed against CD19, a protein expressed on B cells. Rituximab targets CD20, while lenalidomide is an oral immunomodulatory agent. The combination is intended to attack malignant B cells through complementary mechanisms, but the simultaneous use of three active medicines can also increase immune, haematological and infectious complications.
In the published inMIND analysis, adverse events were reported in 99 percent of participants in both groups. Neutropenia occurred in 49 percent of patients receiving tafasitamab and 45 percent of those receiving placebo, while diarrhoea was reported in 38 percent and 28 percent, respectively. The Australian safety information additionally identifies infections, neutropenia, rash, asthenia, pyrexia, thrombocytopenia, anaemia and infusion-related reactions among the commonly reported adverse reactions.
Infections were reported in 68 percent of patients in the tafasitamab-containing arm in the Australian safety summary, including viral and bacterial infections. Serious infections occurred in 26 percent, and tafasitamab can cause severe myelosuppression involving neutropenia, thrombocytopenia and anaemia. The approved information therefore calls for blood-count monitoring and appropriate management of infections before and during treatment.
The practical burden also extends beyond adverse-event percentages. Tafasitamab and rituximab require intravenous administration in a hospital or clinic, with tafasitamab given frequently during the early cycles. Patients may avoid conventional chemotherapy while still making repeated visits for infusions, laboratory testing, infection surveillance and supportive care. Hospital services will need to account for chair time, pharmacy preparation, nursing supervision and the potential management of infusion reactions or cytopenias.
The most accurate interpretation is therefore that Minjuvi offers a chemotherapy-free therapeutic strategy, not a treatment-free experience. Its value will depend on whether the progression-free survival improvement justifies the additional drug exposure and service demands for individual patients.
How should the inMIND evidence be compared with rituximab-based chemotherapy?
One of the central limitations in evaluating the PBS listing is the absence of a direct randomised comparison between tafasitamab plus lenalidomide and rituximab and the rituximab-based chemotherapy regimens used in Australian practice. The inMIND control group received placebo, lenalidomide and rituximab, making the trial well suited to measuring tafasitamab’s contribution to that backbone but not to proving superiority over every competing treatment strategy.
The Pharmaceutical Benefits Advisory Committee accepted that the tafasitamab combination was likely to improve progression-free survival compared with rituximab-based chemotherapy. However, it also said that the submission’s indirect evidence created uncertainty about how fully the observed outcomes would translate into Australian clinical practice. The committee considered the tafasitamab regimen less safe than rituximab-based chemotherapy in its assessment and did not accept the sponsor’s more optimistic survival projections.
This creates a more complex clinical proposition than the phrase “chemotherapy-free” may suggest. Some patients may value avoiding another chemotherapy-containing regimen, particularly after prior exposure or where fitness, tolerability and access to transplantation influence treatment choices. Others may be better served by established immunochemotherapy, cellular therapy, bispecific antibody treatment or another targeted approach, depending on disease characteristics, prior response, treatment timing and available services.
The Australian indication is also precise. Minjuvi is registered with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma grades 1 to 3a. It is not indicated or recommended for relapsed or refractory marginal zone lymphoma outside controlled clinical trials, despite the broader inMIND programme having enrolled some patients with marginal zone lymphoma.
What does Australian reimbursement mean commercially for Specialised Therapeutics and Incyte?
Specialised Therapeutics is commercialising Minjuvi in Australia under an exclusive agreement signed with Incyte Corporation in 2021 covering Australia, New Zealand and Singapore. The reimbursement decision gives the privately held company a funded route into an established hospital oncology market and strengthens its position as a regional partner for therapies developed by larger international biotechnology companies.
For Incyte Corporation, the PBS listing adds another reimbursed territory to tafasitamab’s expanding follicular lymphoma footprint. The company controls the medicine’s global development and commercial rights, while selected regional partners handle distribution in markets where local regulatory, reimbursement and hospital relationships are particularly important.
Incyte recently reported second-quarter 2026 revenue of US$1.67 billion, up 38 percent from the comparable period, with its broader haematology and oncology portfolio benefiting from increased demand for recently launched products, including Monjuvi and Minjuvi. The Australian listing is unlikely to transform Incyte’s financial outlook by itself, but it contributes to the product’s international revenue base and supports the argument that follicular lymphoma can become a meaningful additional indication beyond diffuse large B-cell lymphoma.
Incyte shares closed at US$119.52 on July 31, giving the company a market capitalisation of approximately US$24.9 billion. The stock gained about 1.6 percent over the five trading sessions from July 24 and approximately 5.4 percent from the June 30 close, although it had retreated from a 52-week high of US$132.60 reached after the company’s latest earnings release. Its 52-week range stood at roughly US$75.48 to US$132.60.
Current market sentiment appears constructive toward Incyte’s broader commercial execution and revenue growth, rather than being driven by the Australian reimbursement event alone. The PBS listing is best viewed as an incremental international commercial catalyst that reduces access friction and adds credibility to the tafasitamab franchise.
What will determine whether the PBS listing changes routine follicular lymphoma care?
The first measure of success will be whether eligible Australian patients can move through the authority process and begin treatment without significant administrative or supply delays. Adoption will also depend on clinician familiarity, the availability of infusion appointments and the ability of hospitals to coordinate tafasitamab with oral lenalidomide and rituximab across a treatment period of up to 12 cycles.
The next evidence test will be longer follow-up from inMIND. Clinicians and reimbursement authorities will be watching whether the progression-free survival advantage remains durable, whether overall survival differences emerge and how frequently patients require subsequent therapies. Real-world discontinuation rates, infection burden, dose interruptions and treatment persistence may prove just as important as the trial’s headline hazard ratio.
The PBS listing has removed a major financial barrier, but it has not resolved every clinical sequencing question. Minjuvi now has the regulatory status, reimbursement pathway and Phase 3 evidence needed to compete for a place in Australian practice. Its lasting role will be determined by how consistently the regimen converts delayed progression into manageable treatment, acceptable service demands and outcomes that remain meaningful through the repeated relapses that define follicular lymphoma.
